Number of deaths by cause
. | Inolimomab (n = 49) . | Usual care (ATG) (n = 51) . | ||
---|---|---|---|---|
No. . | % . | No. . | % . | |
aGVHD | 11 | 22.4 | 16 | 31.4 |
cGVHD | 2 | 4.1 | 5 | 9.8 |
Infection | 6 | 12.2 | 12 | 23.5 |
Recurrence of initial disease | 7 | 14.3 | 0 | 0 |
Other | 8 | 16.3 | 8 | 15.7 |
All | 34 | 69.4 | 41 | 80.4 |
. | Inolimomab (n = 49) . | Usual care (ATG) (n = 51) . | ||
---|---|---|---|---|
No. . | % . | No. . | % . | |
aGVHD | 11 | 22.4 | 16 | 31.4 |
cGVHD | 2 | 4.1 | 5 | 9.8 |
Infection | 6 | 12.2 | 12 | 23.5 |
Recurrence of initial disease | 7 | 14.3 | 0 | 0 |
Other | 8 | 16.3 | 8 | 15.7 |
All | 34 | 69.4 | 41 | 80.4 |